INSTITUT JEROME LEJEUNE

Their core work

Institut Jérôme Lejeune is a Paris-based medical research institute dedicated exclusively to Down syndrome (trisomy 21) and related intellectual disabilities — named after the French geneticist who first identified trisomy 21 in 1959. Their work spans from understanding the genetic and epigenetic mechanisms behind Down syndrome comorbidities (mental disorders, obesity, metabolic stress) to developing and testing targeted pharmacological treatments. In their most advanced project, they are contributing to first-in-human clinical trials of CB1 receptor inhibitors designed to improve cognition in people with Down syndrome. They operate as a specialized scientific partner, bringing rare disease expertise and patient-linked research infrastructure that generalist universities cannot easily replicate.

What they specialise in

How they've shifted over time

Their two projects, started just one year apart (2020 and 2021), reveal a clear translational arc within a single disease focus. The first project (GO-DS21) operates at the mechanistic level — mapping gene overdosage, epigenetic dysregulation, and the spectrum of comorbidities that emerge early in life for people with Down syndrome. The second project (ICOD) moves decisively toward clinical application: targeting a specific receptor (CB1), conducting drug safety and efficacy studies, and reaching first-in-human trial stage. In just two funding cycles, they have progressed from understanding the biology to testing a pharmacological fix in patients.

They are moving toward clinical translation, suggesting future collaborations will likely involve drug trials, patient cohorts, regulatory affairs expertise, and pharma partnerships rather than purely basic research.

How they like to work

Institut Jérôme Lejeune has never led an H2020 project — both participations are as a consortium partner, which is typical for a small, highly specialized institute that brings a rare expertise (and potentially patient access) rather than project management capacity. Their consortia are not unusually large, and with only 17 unique partners across two projects, they appear to work in focused, topic-specific teams rather than broad research networks. This makes them a reliable specialist node rather than a consortium hub: they deliver a defined contribution and are most valuable to partners who need rare disease expertise or access to Down syndrome patient communities.

Their network is compact: 17 unique partners spread across 6 countries, all within the European research space and concentrated around two tightly scoped Down syndrome projects. There is no evidence of geographic concentration beyond France, though the partner count per project implies mid-sized consortia of 8–10 organizations each.

What sets them apart

Institut Jérôme Lejeune occupies a nearly unique niche in European research: it is one of very few institutions whose entire research identity is built around a single genetic condition — Down syndrome. That single-disease focus, combined with institutional continuity going back to the founder of trisomy 21 research, gives them unmatched scientific credibility and, crucially, access to patient populations that no generalist hospital or university can easily replicate. For any consortium building a project involving intellectual disabilities, trisomy 21, or cognitive drug development in rare pediatric or adult populations, they are among a handful of partners in Europe who can provide both the science and the patients.

Highlights from their portfolio

• GO-DS21
  The largest of their two funded projects (EUR 344,044), it addresses the full spectrum of Down syndrome comorbidities from a genetic and epigenetic standpoint — a foundational mechanistic study that underpins their clinical work.
• ICOD
  Represents a significant translational step: advancing CB1 receptor inhibitors into first-in-human clinical trials specifically to improve cognition in Down syndrome, placing IJL at the frontier of rare disease pharmacology.